02991cam a2200421 i 4500 20032 20032 17746819 OSt 20250925070933.0 130521s2014 enka b 001 0 eng 2013012165 9780443112201 hardback 17746819 DLC eng DLC rda DLC pcc RC268.4 .M675 2014 616.994 23 Bocklage Therese Molecular oncology 3rd ed Philadephia Elsevier 2024 xix,969p color illustrations ; 29 cm text rdacontent unmediated rdamedia volume rdacarrier Includes bibliographical references and index. Machine generated contents note: Part I; Part II; Part III; Part IV. Pharmacologic Targeting of Oncogenic Pathways. "The genomic era has allowed enormous strides in our understanding of the molecular changes that underlie malignant transformation. Mutations have been discovered that are critical drivers of large cross-sections of human cancers. These discoveries have allowed us to find drugs that target these drivers and make important strides in treatment. Genomics and high-throughput technologies have illuminated the complexity of cancer and the facility with which cancers adapt during their natural history. The field is evolving rapidly with new discoveries and new drugs reported monthly. This book is a timely foundation for understanding in context the origins of molecular oncology and its future directions. The content reviews available technologies for the analysis of cancer tissues and genes; summaries of key oncogenic pathways from a molecular perspective; the technologies, pathways and targeted therapies of a wide range of human malignancies; and new pharmacologic therapies that have a common mechanistic target"-- Provided by publisher. "This book was conceived more than five years before its publication date. It was intended to provide a resource that summarized technology, biochemistry, molecular pathophysiology, and targeted therapeutics. As contributors were being recruited and chapters written the field that was being described changed at an accelerating pace. It is a tribute to scientific progress that volumes like this one are out-of-date as they are published, but books like this are not meant to contain the most current laboratory discovery or report the most recent FDA approval"-- Provided by publisher. Cancer Molecular aspects. Tumor markers. Carcinogenesis. Gelmann, Edward P., 1953- Sawyers, Charles L. Rauscher, F. J. (Frank Joseph), 1957- 7 cbc orignew 1 ecip 20 y-gencatlg ddc BK 0 0 ddc 0 0 NF SHMSL SHMSL LS 2025-09-25 616.994 BOC M000005119 2025-09-25 2025-09-25 BK 0 0 ddc 0 0 NF SHMSL SHMSL LS 2025-09-25 616.994 BOC M000005120 2025-09-25 2025-09-25 BK